Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR.

[1]  B. Strandvik,et al.  Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  E. Schneider-Futschik,et al.  Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method. , 2020, ACS pharmacology & translational science.

[3]  P. Burgel,et al.  Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis , 2020, Journal of pediatric gastroenterology and nutrition.

[4]  K. Carson,et al.  A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  Jérémy Dana,et al.  Hepatic manifestations of cystic fibrosis. , 2020, Current opinion in gastroenterology.

[6]  D. Caimmi,et al.  Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. , 2020, American journal of respiratory and critical care medicine.

[7]  C. Flask,et al.  Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients , 2019, World journal of hepatology.

[8]  P. Lewindon,et al.  Accuracy of Transient Elastography Data Combined With APRI in Detection and Staging of Liver Disease in Pediatric Patients With Cystic Fibrosis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  B. Linnane,et al.  GP274 Liver tests in F508del homozygous cystic fibrosis patients on orkambi , 2019, Abstracts.

[10]  I. Sermet-Gaudelus,et al.  Predictive factors for lumacaftor/ivacaftor clinical response. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[11]  G. Sawicki,et al.  Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. , 2019, The Lancet. Respiratory medicine.

[12]  H. Corvol,et al.  Modifier genes in cystic fibrosis-related liver disease , 2019, Current opinion in gastroenterology.

[13]  P. Böelle,et al.  Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients , 2018, Hepatology.

[14]  J. Goss,et al.  Obliterative Portal Venopathy Without Cirrhosis Is Prevalent in Pediatric Cystic Fibrosis Liver Disease With Portal Hypertension. , 2019, Clinical Gastroenterology and Hepatology.

[15]  H. Sokol,et al.  Diet‐Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice , 2018, Hepatology communications.

[16]  A. Körner,et al.  New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, γ‐glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage , 2018, Hepatology.

[17]  Jaap Stoker,et al.  MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis. , 2017, Radiology.

[18]  J. Li,et al.  Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients. , 2017, Journal of visualized experiments : JoVE.

[19]  M. Trauner,et al.  Cystic Fibrosis–related Liver Disease: Research Challenges and Future Perspectives , 2017, Journal of pediatric gastroenterology and nutrition.

[20]  S. Stanojevic,et al.  Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. , 2017, The Lancet. Respiratory medicine.

[21]  A. Berzigotti,et al.  Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy , 2017, Gastroenterology report.

[22]  R. Fiorotto,et al.  The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity , 2016, Hepatology.

[23]  T. Kotsimbos,et al.  Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[24]  M. Knowles,et al.  Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  C. Minard,et al.  Aspartate aminotransferase to platelet ratio and fibrosis‐4 as biomarkers in biopsy‐validated pediatric cystic fibrosis liver disease , 2015, Hepatology.

[26]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[27]  R. Houwen,et al.  Increase of Serum &ggr;-Glutamyltransferase Associated With Development of Cirrhotic Cystic Fibrosis Liver Disease , 2015, Journal of pediatric gastroenterology and nutrition.

[28]  Ying Sun,et al.  Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: An updated meta‐analysis , 2011, Hepatology.

[29]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[30]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[31]  I. Vlachonikolis,et al.  Spleen length in childhood with US: normal values based on age, sex, and somatometric parameters. , 2004, Radiology.

[32]  F. Ratjen,et al.  Cystic fibrosis , 2003, The Lancet.

[33]  G. Erbaş,et al.  Normal liver, spleen, and kidney dimensions in neonates, infants, and children: evaluation with sonography. , 1998, AJR. American journal of roentgenology.